Current Management of Traumatic Macular Holes

Table 3

Literature review of reports on vitrectomy outcomes for TMH.

References	Number of cases	Mean age (yrs)	Adjuvants	Tamponades	Anatomic success	Functional success
Rubin et al., 1995 [40]	12	15	TGF-β2	C3F8	67%	67%
García-Arumí et al., 1997 [41]	14	22	Platelet concentrate	SF6	93%	93%
Barreau et al., 1997 [42]	4	17	Platelet concentrate	C3F8	75%	50%
Margherio et al., 1998 [43]	4	13	Autologous plasmin	C3F8	100%	100%
Amari et al., 1999 [44]	23	27	None	SF6	70%	87%
Chow et al., 1999 [45]	16	25	Autologous plasmin	C3F8	94%	69%
Johnson et al., 2001 [6]	25	23	Serum or none	C3F8	96%	84%
Kuhn et al., 2001 [46]	17	26	None	SF6	100%	94%
Wachtlin et al., 2003 [47]	4	13	Platelet concentrate	SF6	100%	100%
Wu et al., 2007 [48]	13	10	Plasmin	C3F8 or sio	92%	92%
Ghoraba et al., 2012 [49]	22	27	None	C3F8 or sio	82%	n/a
Azevedo et al., 2013 [36]	4	12	None	Gas	100%	75%
Hou and Jiang, 2013 [39]	54	27	Platelet concentrate	SF6/C2F6/C3F8	89%	52%
Miller et al., 2015 [33]	11	21	None	Gas or sio	45%	n/a
Yuan et al., 2015 [31]	26	32	None	C3F8	69%	27%
Abou Shousha, 2016 [50]	12	23	None	SF6	100%	n/a

one operation; lines’ visual acuity improvement; sio: silicone oil.